Hefei Jinkesi Biotechnology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Hefei Jinkesi Biotechnology Co., Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. The portfolio also extends into Class 8 (Hand Tools) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include QEUCI and IPKMARAS. The owner is based in Hefei, Anhui.
Meichonghu Rd, Shuangfeng EDZ.,Changfeng
916-25, Bldg A, Shuangfeng Zhigu ITP.
Hefei, Anhui 230000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Hefei Jinkesi Biotechnology Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Hefei Jinkesi Biotechnology Co., Ltd. have?
Hefei Jinkesi Biotechnology Co., Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Hefei Jinkesi Biotechnology Co., Ltd. file in?
Hefei Jinkesi Biotechnology Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 8 (Hand Tools). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Hefei Jinkesi Biotechnology Co., Ltd.'s most well-known trademarks?
Hefei Jinkesi Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as QEUCI and IPKMARAS. These are among 2 currently registered trademarks in the portfolio.
What is Hefei Jinkesi Biotechnology Co., Ltd.'s trademark registration success rate?
Hefei Jinkesi Biotechnology Co., Ltd. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.